VIR

Vir Biotechnology Inc

Add to Watchlist

Advanced Chart

5.250

0(0.000%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

5.250

Open

5.250

VWAP

Vol

6.33K

Mkt Cap

725.75M

Low

5.250

Amount

EV/EBITDA(TTM)

Total Shares

136.06M

-75.91M

EV/OCF(TTM)

P/S(TTM)

34.43

Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes infectious disease programs for chronic hepatitis delta and chronic hepatitis B infections and multiple dual-masked T-cell engagers across validated targets in solid tumor indications. It also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies. Tobevibart is an investigational neutralizing monoclonal antibody (mAb) that has been engineered for immune engagement and targets a conserved region on the hepatitis B surface antigen (HBsAg). Elebsiran is an investigational HBV-targeted small interfering RNA (siRNA) that reduces HBsAg. Its pipeline includes VIR-5818, VIR-5500, VIR-5525, and HIV Cure. It also has rights to the PRO-XTEN masking platform for oncology and infectious disease.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q2

FY2025Q3

FY2025Q4

2.72M

-11.48%

-0.718

-29.58%

2.72M

+14.37%

-0.709

-54.53%

2.72M

-78%

-0.706

-7.12%

Estimates Revision

The market is revising No Change the revenue expectations for Vir Biotechnology, Inc. (VIR) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -14.22%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Down

-14.22%

In Past 3 Month

9 Analyst Rating

221.14% Upside

Wall Street analysts forecast VIR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VIR is 16.86 USD with a low forecast of 12.00 USD and a high forecast of 31.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

7 Buy

2 Hold

0 Sell

Strong Buy

221.14% Upside

Current: 5.250

Low

12.00

Averages

16.86

High

31.00

221.14% Upside

Current: 5.250

Low

12.00

Averages

16.86

High

31.00

Raymond James

initiated

$12

2025-07-11

Reason

Raymond James

Price Target

$12

2025-07-11

initiated

Reason

Raymond James initiated coverage of Vir Biotechnology with an Outperform rating and $12 price target.

Raymond James

Sean McCutcheon

Outperform

initiated

$12

2025-07-11

Reason

Raymond James

Sean McCutcheon

Price Target

$12

2025-07-11

initiated

Outperform

Reason

Raymond James analyst Sean McCutcheon initiated coverage of Vir Biotechnology with an Outperform rating and $12 price target. Vir's VIR-5500 shows "compelling" early Phase 1 data in heavily treated metastatic castration-resistant prostate cancer patients, and VIR-5500 is well-positioned to capture share in the large and growing mCRPC market, the analyst tells investors in a research note. The firm's constructive view is balanced by competitive headwinds in prostate cancer, as well as the company's high burn rate and need for additional financing to bring VIR-5500 through pivotal studies.

H.C. Wainwright

Buy

downgrade

$110 -> $15

2025-05-20

Reason

H.C. Wainwright

Price Target

$110 -> $15

2025-05-20

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on Vir Biotechnology to $15 from $110 and keeps a Buy rating on the shares. The company's updated 24-week off-treatment data from the Phase 2 program did not meet functional cure thresholds that would be needed to support a Phase 3 investment in the absence of a global partner in chronic hepatitis B virus, the analyst tells investors in a research note. The firm believes chronic hepatitis delta virus infection is now Vir's clear lead value driver in hepatitis.

Goldman Sachs

Paul Choi

Strong Buy

Maintains

$28 → $21

2025-04-17

Reason

Goldman Sachs

Paul Choi

Price Target

$28 → $21

2025-04-17

Maintains

Strong Buy

Reason

HC Wainwright & Co.

Patrick Trucchio

Strong Buy

Reiterates

$110

2025-02-28

Reason

HC Wainwright & Co.

Patrick Trucchio

Price Target

$110

2025-02-28

Reiterates

Strong Buy

Reason

Barclays

Gena Wang

Buy

Maintains

$26 → $31

2025-02-28

Reason

Barclays

Gena Wang

Price Target

$26 → $31

2025-02-28

Maintains

Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Vir Biotechnology Inc (VIR.O) is -1.93, compared to its 5-year average forward P/E of -7.13. For a more detailed relative valuation and DCF analysis to assess Vir Biotechnology Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-7.13

Current PE

-1.93

Overvalued PE

9.74

Undervalued PE

-24.00

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-3.40

Current EV/EBITDA

-0.17

Overvalued EV/EBITDA

9.08

Undervalued EV/EBITDA

-15.88

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Strongly Overvalued

5Y Average PS

23.20

Current PS

70.91

Overvalued PS

40.49

Undervalued PS

5.92

Financials

Annual

Quarterly

FY2025Q1

YoY :

-94.62%

3.03M

Total Revenue

FY2025Q1

YoY :

+74.17%

-139.56M

Operating Profit

FY2025Q1

YoY :

+85.31%

-120.97M

Net Income after Tax

FY2025Q1

YoY :

+83.33%

-0.88

EPS - Diluted

FY2025Q1

YoY :

-28.33%

-79.75M

Free Cash Flow

FY2025Q1

YoY :

+0.10%

100.00

Gross Profit Margin - %

FY2025Q1

YoY :

+106.78%

-2.02K

FCF Margin - %

FY2025Q1

YoY :

+3345.56%

-3.99K

Net Margin - %

FY2025Q1

N/A

ROIC

Trading Trends

Insider

Insiders areSelling! The selling amount has increased 946.49% over the last month.

Sold

0-3

Months

185.2K

USD

3-6

Months

474.2K

USD

6-9

Months

848.7K

USD

0-12

Months

95.0K

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds areSelling! The selling amount has increased 3690.48% over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

573.1K

Volume

6-9

Months

15.1K

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

1.1M

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders areSelling! The selling amount has increased 946.49% over the last month.

Sold

0-3

Months

185.2K

USD

3-6

Months

474.2K

USD

6-9

Months

848.7K

USD

0-12

Months

95.0K

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

VIR News & Events

Events Timeline

2025-07-24 (ET)

2025-07-24

08:26:24

Vir Biotechnology doses first patient in VIR-5525 trial

2025-05-09 (ET)

2025-05-09

06:07:50

Vir Biotechnology reports data from MARCH Phase 2 clinical study

2025-05-07 (ET)

2025-05-07

17:04:26

Vir Biotechnology reports Q1 EPS (88c), consensus (84c)

News

9.0

07-24Newsfilter

Vir Biotechnology Announces First Patient Dosed in Phase 1 Clinical Trial of EGFR-Targeting PRO-XTEN™ Dual-Masked T-Cell Engager VIR-5525 for the Treatment of Solid Tumors

2.0

07-10NASDAQ.COM

$VIR stock is up 13% today. Here's what we see in our data.

1.0

05-20Newsfilter

Vir Biotechnology to Participate in TD Cowen 6th Annual Oncology Innovation Summit